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Dendritic cells are a heterogeneous group of leukocytes that initiate and regulate immune responses, especially T-cell-mediated immune responses (1) . Although only now are relationships among dendritic cell subpopulations found at different body sites and in different settings being delineated, several dendritic cell subpopulations are clearly distinct. Epidermal Langerhans cells are skin-resident dendritic cells (Fig.  P1 ) that can be distinguished from other dendritic cells by several criteria, including expression of a pattern-recognition receptor protein termed "Langerin." Here, we take advantage of this Langerhans cell characteristic and genetic engineering to study the involvement of another protein, EpCAM (CD326), in Langerhans cell movement. Under steady-state conditions and after stimulation, Langerhans cells migrate from the skin to lymph nodes that are in close proximity, and this process is thought to be critical for Langerhans cell function. We determined that the motility and migratory activity of Langerhans cells that lack EpCAM is attenuated and that regulation of a skin inflammatory response by EpCAM-deficient Langerhans cells is compromised.
The ability of Langerhans cells to localize and persist in epidermis probably is regulated by intercellular adhesion molecules that they express (e.g., E-cadherin and EpCAM). Unlike epidermal keratinocytes, which are shed from skin surfaces within days to weeks, most Langerhans cells maintain their relative positions in epidermis for much longer periods. However, noxious stimuli cause Langerhans cells to extend and retract their dendritic projections between keratinocytes actively, to translocate within the epidermis, and to leave the epidermis to exert immune regulatory activity (2) . Interestingly, activated Langerhans cells also can extend dendrites through structures termed "tight junctions" that contribute to the epidermal physical barrier and then capture antigens that are present on skin surfaces (3).
In the present study, we assessed the involvement of EpCAM, a molecule that has been implicated in cancer invasiveness (4, 5) , in the movement of Langerhans cells within and emigration from mouse epidermis. Like Langerhans cells, cancer cells also migrate from epithelia (including skin) to lymph nodes during the process of metastasis, and common mechanisms may be involved. Understanding of EpCAM function, especially in physiologic contexts, is incomplete. EpCAM has been reported both to enhance and to attenuate intercellular adhesion and, more recently, to transmit extracellular signals to the nucleus as well. Several years ago, to explore EpCAM function in vivo, we generated knockout mice in which the gene that encodes EpCAM was inactive. Because these mice had embryonic-lethal placental defects, postnatal EpCAM-knockout animals could not be obtained, and studies of Langerhans cells and other EpCAM-expressing cells were not possible. To circumvent this problem, we used a genetic engineering methodology termed "recombineering" to generate conditional knockout mice in which only Langerhans cells were EpCAM deficient. To do so, we incorporated loxp sites into the mouse EpCAM gene. (Loxp sites are short stretches of genetic material that are recognized by the bacteriophage enzyme Cre recombinase.) If two loxp sites are present on the same DNA strand in were imaged beginning 18 h after application of a contact sensitizer that stimulates Langerhans cell movement. Images were acquired using two-photon intravital microscopy. Note that control Langerhans cells move dendrites and cell bodies considerably over the 1-h observation period, whereas an EpCAM-deficient Langerhans cell appears to be fixed.
close proximity to each other, Cre introduces breaks in the DNA at each loxp site and rejoins the ends, deleting intervening sequences in the process. We inserted loxp sites flanking exons 1 and 2 of the EpCAM gene, generating transgenic mice (EpCAMcKO mice). We anticipated that EpCAM-cKO mice could be used to generate progeny that lacked EpCAM in various tissues by crossing EpCAM-cKO mice with existing genetically engineered mice selectively expressing Cre recombinase in cells/tissues of interest. The accompanying report describes our initial experience with EpCAM-cKO mice that we used in conjunction with mice that express Cre only in Langerhans cells (LangerinCre transgenic mice), successfully generating mice with EpCAMdeficient Langerhans cells (LC/EpCAM-cKO mice).
The EpCAM gene was inactivated efficiently in Langerhans cells in LC/EpCAM-cKO mice, and Langerhans cells in these mice did not express EpCAM protein. Langerhans cell numbers in LC/EpCAM-cKO mice were increased twofold, indicating that EpCAM is not required for Langerhans cell development or localization in skin. Furthermore, loss of EpCAM did not cause changes in Langerhans cell surface phenotype or T-cell stimulatory activity in vitro, and EpCAM-deficient Langerhans cells still could be activated readily in vivo. Langerhans cell migration and motility in LC/EpCAM-cKO mice were strikingly abnormal, however. The ability of EpCAM-deficient Langerhans cells to emigrate from epidermis was decreased both in vitro and in vivo. EpCAM-deficient Langerhans cells also did not migrate efficiently to regional lymph nodes after exposure to antigens. Correspondingly, contact hypersensitivity responses were increased in LC/EpCAM-cKO mice to the same extent seen in Langerhans cell-deficient mice. This observation definitively links Langerhans cell migration to regulation of skin inflammation. In an important control experiment, we showed that dissociated EpCAM-deficient Langerhans cells migrated efficiently in response to chemokine in vitro, arguing against a general motility defect in these cells.
The superficial location of Langerhans cells in skin allowed real-time imaging of EpCAM-deficient and control (EpCAMexpressing) Langerhans cells using multiphoton immunofluorescence intravital microscopy. This approach revealed that dendrite motility and activation-induced movement within the epidermis were decreased dramatically in EpCAM-deficient Langerhans cells (Fig. P1) . This behavior suggests that EpCAMdeficient Langerhans cells adhere to keratinocytes more tightly than do EpCAM-expressing Langerhans cells and that the ability of EpCAM-deficient Langerhans cells to detach from keratinocytes after activation is diminished. Thus, our findings imply that, at least in this setting, EpCAM appears to be anti-rather than proadhesive.
These experiments were possible only because EpCAM could be targeted selectively in Langerhans cells, Langerhans cells could be differentiated from surrounding cells easily in situ, and the epidermal location of Langerhans cells allowed real-time imaging in vivo. Based on studies conducted in this unique experimental setting, we suggest that EpCAM also may attenuate adhesion in developing epithelia and in tumors, facilitating tissue morphogenesis and metastasis. Thus, molecular regulators of Langerhans cell movement may have broader biologic roles, and elucidation of the mechanisms that enable Langerhans cell motility and migration may promote the development of therapeutics with immunomodulatory and anticancer activities.
